Radiation Oncology

Do you include the whole seminal vesicles and prostate, or just the whole seminal vesicles? Do you add external iliac lymph node coverage in this scen...

1 Answer available

How would you approach a small mucinous adenocarcinoma of the anal verge (without anal canal involvement) with positive margins after resection?

Further surgery is not possible.

2 Answers available

How would you manage a patient with Lynch syndrome who is s/p surgery and pelvic RT 20+ years ago for endometrial carcinoma with a new T3N0M0 squamous cell carcinoma of the anus?

The patient refuses surgery.

2 Answers available

Do you use a metal biliary stent as a fiducial marker for cholangiocarcinoma?

Do you worry about migration or scatter dose from the metal?

2 Answers available

What dose/fractionation would you choose for resected tail of pancreas adeno with positive margin, node negative?

Plan to give adjuvant chemotherapy.

1 Answer available

Would you consider chemoradiation to the primary in a patient with resectable pancreatic cancer s/p neoadjuvant chemotherapy found to have single liver metastasis on re-staging?

If so, what dose and fractionation?

1 Answer available

How would you approach a mucinous adenocarcinoma of the anal verge without anal canal involvement, status post excision with positive margins but without the possibility of additional surgery?

Given this rare histology, would you treat this patient as a skin cancer or as an anal adenocarcinoma with inguinal nodal coverage?

1 Answer available

Should anal cancer patients undergoing definitive chemoradiation be put on a treatment break for neutropenic status?

Is this practice still relevant to the modern IMRT approach where skin toxicity is much lower?

1 Answer available

Is there a role for pre-operative RT (+/-chemo) for a borderline resectable Klatskin tumor as an attempt to try to get them to surgery?

1 Answer available

How do you treat unresectable pancreatic adenocarcinoma invading into the duodenum?

Would you consider "neoadjuvant" RT to 45-50.4 Gy followed by a resimulation and a boost to a "definitive" dose of 54+ Gy depending upon disease respo...

1 Answer available

What chemotherapy regimen do you recommend with radiation therapy for cervical esophageal squamous cell carcinoma?

The upfront plan is to use a definitive radiation dose of 66 Gy. My reading supports the use of 5FU + cisplatin but another doctor is recommending FOL...

1 Answer available

For borderline resectable pancreas treated with induction chemo therapy and minimal radiographic response, if unable to do SBRT, do you prefer 36/15 or 50.4/28 (given that is where we have more data)?

The concern being that if patient does not go to surgery, you have delivered lower BED with 36/15.

1 Answer available

What constraints do you use for the gallbladder when giving liver SBRT to lesions close to the gallbladder?

1 Answer available

How soon after ChemoRT for a head and neck cancer can you safely initiate esophageal dilation?

3 Answers available

When is SBRT or hypofractionated radiation appropriate as adjuvant treatment for pancreatic cancer?

What are the targets (tumor bed, positive margin, nodes etc.)?

4 Answers available

In what situations can short course RT (5Gy x 5fx) be used instead of chemoRT for rectal cancer?

6 Answers available

Do you recommend definitive chemoradiation for unresectable gastric adenocarcinoma in a medically unfit patient?

If so, what dose-fractionation regimen do you utilize? What are your target volumes?

2 Answers available

What is the appropriate radiation dose/volume for perianal basal cell carcinoma?

Should concurrent chemotherapy be given? How would you modify the regimen in elderly/frail patients?

1 Answer available

Would you offer liver SBRT to a patient with a history of a liver transplant?

Assuming good liver function currently, without evidence for recurrent cirrhosis? Would your decision be affected if it was a primary HCC vs Liver me...

1 Answer available

If a patient has distal esophageal adenocarcinoma and a PET+ left supraclavicular lymph node, and nothing in between, would you cover the entire esophagus? Both supraclavicular fields?

1 Answer available

What role, if any, is there for Y90 in metastatic gallbladder cancer to the liver?

1 Answer available

Can total neoadjuvant therapy be considered an option equivalent to standard of care treatment for patients with T3N0 or T3N1 rectal adenocarcinoma?

Or should total neoadjuvant therapy be reserved for bulkier disease (T4N2)?

2 Answers available

What adjuvant therapy do you give after surgery to patients with gastric CA who undergo 3 cycles of FLOT with no tumor effect on pathology and maintain good PS?

I understand the perioperative trials are not based on tumor regression in cancer cells.

5 Answers available

How do you approach rectal cancer with a solitary bone metastasis that is biopsy proven?

Do you recommend definitive therapy? Would your approach change if there are more than 1 site of bone metastases, such as 2-3?

1 Answer available

Do you recommend neoadjuvant radiation or chemoradiation for patients with T1-2 N0 adenocarcinoma of the anal canal prior to APR?

2 Answers available

What anal squamous cell carcinoma patients, if any, do you take to 59.4 Gy?

1 Answer available

What dose do you use for squamous cell carcinoma of the cervical esophagus?

2 Answers available

When treating node positive anal squamous cell carcinoma, dose your lymph node boost include only gross disease with margin or do you boost the entire nodal region?

1 Answer available

Would you still offer adjuvant chemoradiation therapy to a patient with pT3 pN1a rectal cancer who did not receive any neoadjuvant treatment, and whose adjuvant treatment is delayed by 4 months due to post-operative complications?

Is there any data to support delayed treatment?

1 Answer available

In what situations do you obtain both a pelvic MRI and EUS for rectal cancer staging and treatment planning?

For instance, in borderline cases for neoadjuvant therapy (e.g. T2N1 disease), should both be obtained to increase accuracy?

1 Answer available

Is it appropriate to treat unresectable secretory insulinoma of tail of the pancreas with radiation therapy?

What dose would you recommend? Any role for systemtic therapy?

1 Answer available

In a patient with gastric adenocarcinoma with +peritoneal cytology status post an R1 resection, would you consider post operative chemoradiation?

2 Answers available

Would you consider prone SBRT (with solid image guidance techniques) if bowel is lying on a target, for instance bowel surrounding an oligometastatic lymph node or next to a kidney tumor?

1 Answer available

Would you recommend adjuvant radiation therapy to a T4N0 colon cancer with invasion into other organs or the abdominal wall status post R1 resection?

Would you cover elective lymph nodes?

3 Answers available

Do you have any specific bowel constraints when treating patients with palliative radiation 3000/10?

Do you look at max dose or are there specific volumetric constraints you use for the small or large bowel?

1 Answer available

In patients receiving neoadjuvant CRT for cN+ rectal cancer, do you expand your elective nodal volumes to include the external iliac chain or to extend more superiorly along the common iliac chain?

Do you boost the positive nodes beyond your standard pelvic dose?

4 Answers available

What is the role of liver SBRT in the setting of an excellent interventional radiology program?

Our hospital has an aggressive and talented interventional radiology group. We have wanted to start a stereotactic liver radiotherapy program but are ...

3 Answers available

When do you consider total neoadjuvant therapy (chemotherapy and chemoradiation) for rectal cancer?

1 Answer available

For gastric cancer receiving FLOT perioperatively with negative margins but multiple positive nodes, do you offer postoperative chemoRT?

1 Answer available

How do you manage an anal SCC status post a non-oncologic excision of a 2-3 cm primary and positive excisional biopsy of an inguinal node with pathology revealing LVSI, positive surgical margins, and more regional lymph nodes on PET?

What dose do you take the primary to?

1 Answer available

How do you decide what elective lymph node stations to include in your treatment volume for cervical and upper and middle thoracic esophagus cancer?

1 Answer available

In patients witih locally advanced pancreatic cancer, how long would you wait after 1st line induction chemotherapy with FOLFIRINOX before you image for assessment of response and deciding about 2nd-line therapy?

1 Answer available

What is your general approach to treating bleeding gastric masses with palliative RT?

Do you have any preferred dose fractionation schedules? What kind of margins do you use?

3 Answers available

Would you offer radiation therapy for pleural- or peritoneal-based pseudomyxoma peritonei?

If so, how would you approach your radiotherapeutic plan and what dose-fractionation would you utilize?

1 Answer available

Would you offer adjuvant chemoRT to a patient with pancreatic adenocarcinoma who underwent neoadjuvant therapy with FOLFIRINOX and SBRT but had a positive (neck) margin on resection and is now s/p adjuvant chemotherapy?

1 Answer available

Would you recommend SBRT for locally advanced pancreatic adenocarcinoma invading the stomach s/p multiple rounds of chemotherapy?

1 Answer available

In light of the 2015 ASTRO plenary session presentation about involved-field radiation vs elective nodal radiation therapy, are you including elective nodal fields (celiac, mediastinal, supraclavicular) in the treatment of locally advanced esophageal cancer?

1 Answer available

How long after pancreatic SBRT do you wait to re-image?

This will influence the decision to operate or not, so you want to give it enough time to see a response, but given that it's a disease predisposed to...

1 Answer available

How would you approach a patient with locally recurrent esophageal carcinoma who is s/p previous chemoRT and refuses salvage surgery?

1 Answer available

Would you offer additional radiation therapy in a medically inoperable patient with rectal adenocarcinoma who has a persistently palpable tumor after definitive chemoradiation therapy?

Would you consider a re-biopsy after chemoRT to confirm viable tumor and if so, how long would you wait after chemoRT before biopsy? If you did ...

3 Answers available

When would you offer adjuvant RT after R0 resection for a distal esophageal adenocarcinoma?

If so, what would your target encompass?

1 Answer available

What dose-fractionation would you utilize when treating an elderly patient with local-only pancreatic cancer who is not eligible for systemic therapy or surgery?

1 Answer available

Would you recommend pre operative (chemo)radiotherapy for a patient with a T3 N0 low rectal cancer in a patient with active Crohn's disease?

Colonoscopy reveals inflammation in the colon and rectum due to Crohn's and patient also has perianal fistula due to Crohn's.

1 Answer available

Do you treat elective nodes in unresectable pancreas when treating with 15fx?

Do you use concurrent Xeloda?

1 Answer available

Is there any data comparing neoadjuvant pancreatic SBRT vs standard fractionation in terms of its ability to convert unresectable tumors to resectable tumors?

What percentage of unresectable T4N0 pancreatic body adenocarcinomas with celiac axis involvement and no response to 6c chemo, will convert to resecta...

1 Answer available

Do you use any dose constraints for the spleen while delivering abdominal radiation therapy?

1 Answer available

How do you time same-day chemotherapy and radiation for patients undergoing concurrent chemoRT?

For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...

3 Answers available

Would you treat the supraclavicular nodes electively for a patient with esophageal adenocarcinoma originating in the mid-esophagus but extending above the carina?

2 Answers available

What is the most appropriate radiation dose and volume for elderly and/or frail patients with advanced SCC of the anal canal not receiving chemotherapy to attain durable local control?

5 Answers available

When a large malignant appearing GI mass is encountered on endoscopy but biopsies show dysplasia or carcinoma in situ, would you recommend additional biopsies or proceed with treatment for invasive cancer?

I am currently managing two patients (one esophageal and one anal) with this scenario and the referring physicians and patients are reluctant to under...

4 Answers available

Do you consider adjuvant radiation for low grade T1bN0 gallbladder adenocarcinoma with negative margins after oncologic resection?

The data is scarce- do you recommend chemotherapy only or would you consider RT for local control?

1 Answer available

How would you approach oligometastatic (solitary) recurrence with previously resected pancreatic adenocarcinoma and adjuvant chemotherapy with a prolonged disease-free interval?

Is there a role for SBRT with or without the addition of systemic therapy?

3 Answers available

How do you manage a patient who presents with a tracheoesophageal fistula from a lung or esophageal primary that is non-metastatic?

As a for instance, a centrally located primary tumor with mediastinal adenopathy that results in a TE fistula? Currently we would recommend esophagea...

4 Answers available

What image guidance do you use when treating rectal and anal cancers?

3 Answers available

When using oral contrast for simulation, how much prior to simulation do you have patients drink the contrast?

Does this vary depending on the site you are treating, i.e. abdomen vs pelvis?

3 Answers available

What neoadjuvant approach is best for an adenocarcinma of the GE junction (arising in Barret's) with a large hiatal hernia?

Would you recommend neoadjuvant chemotherapy to spare the stomach?

1 Answer available

Would you recommend adjuvant chemoradiation after adjuvant chemotherapy for a patient with pancreatic adenocarcinoma s/p a whipple resection with negative margins?

What pathologic factors would you use to make your recommendation?

1 Answer available

Should definitive concurrent chemoRT be offered to patients with anal canal SCCa with common iliac nodal involvement (by definition M1 disease) without evidence for other distant disease?

2 Answers available

How would you treat a patient with locally and distant recurrent rectal cancer who has previously received chemoradiation but now presents with pain and bleeding from the site of local recurrence?

1 Answer available

How do you approach treatment planning for preoperative radiation therapy in gastric cancer?

If considering that it is not gastroesophageal junction, what margin do you place on the clipped GTV to formulate CTV? Is there any role for SIB to PE...

1 Answer available

When treating rectal cancer with conventional neoadjuvant chemoradiation (45 Gy to pelvis with boost to 50.4 Gy), what volume do you use for the boost?

There is no RTOG consensus on boost volume, except to say that it should include the entire mesorectum/presacral region at involved levels + 2 cm in c...

2 Answers available

In patients with oligometastatic disease, would you offer SBRT to a metastatic lymph node abutting the trachea and/or esophagus?

If so, what dose and dose constraints would you consider? How would you counsel the patient about risk of trachesophageal fistula?

1 Answer available

How do you create an ITV for liver SBRT (metastatic lesions) when you don't have a 4D-CT or fiducials?

Is it sufficient to use fluoroscopy to assess total motion, fuse MRI and PET to create an ITV, and use abdominal compression to limit motion?

3 Answers available

In the case of a thoracic esophageal cancer that will require extensive volume coverage, >2/3 of the esophagus, do you prophalactically prescribe a feeding tube or observe?

3 Answers available

Would you recommend adjuvant chemoradiation for a resected ampullary adenocarcinoma?

What features would make you more likely to recommend radiation therapy with chemotherapy?

1 Answer available

What would you recommend for a patient with a new or locally recurrent anal cancer s/p chemoRT for anal cancer 15 years ago?

1 Answer available

What treatment would you recommend for a 3 cm basal cell carcinoma of the perianal skin with anal canal involvement?

The patient has no evidence of lymph node involvement.

1 Answer available

How would you treat oligoprogressive metastatic GIST to the liver with a single enlarging liver lesion while on imatinib and no other evidence of active disease, where surgery and RFA are not possible?

If you would recommend radiation therapy, what dose-fractionation would you utilize?

1 Answer available

Are there circumstances when you would consider re-irradiation of the esophagus in a patient who is not a surgical candidate or declines surgery?

1 Answer available

How would you recommend treating locally recurrent pancreatic cancer?

In a patient who has undergone resection and adjuvant chemotherapy who then recurs locally, how would you recommend treating? Would you treat ju...

1 Answer available

For postoperative gastric patients status post total gastrectomy, how do you approach anastamotic coverage?

Detailed instructions regarding lymph node coverage have been published, but how do you think about coverage of the anastamoses from the gastrectomy?

1 Answer available

Do you regularly utilize antiemetic or GI prophylaxis when treating abdominal sites with SBRT?

What timing do you recommend? What drug and what dose do you use?

1 Answer available

How would you approach a young patient with metastatic rectal cancer and a painful local recurrence who underwent chemoRT to 50.4 Gy two years ago and declined surgery?

1 Answer available

How would you mange true anal margin squamous cell carcinoma (with no involvement of anal canal) if wide local excision cannot be done and chemoradiation therapy is being used instead?

Anal cancer guidelines mostly refer to anal canal tumors with less information about tumors of skin in perianal area (ie true anal margin). Would IMR...

2 Answers available

How would you manage a male with a prior history of localized prostate cancer s/p radiation to prostate only (two years ago), who now presents with a T1N0 squamous cell carcinoma of the anus?

Would your management change if the prostate and lymph nodes were treated with radiation two years ago?

2 Answers available

How would you treat very locally aggressive rectal cancer extending into muscle and causing internal iliac tumor thrombus, in a patient who is not a surgical candidate?

What volumes and doses of radiation would you recommend? To what dose would you limit the rectum, especially in a patient with no salvage surgical opt...

1 Answer available

How do you approach patients with squamous cell carcinoma of anal canal with ano-vaginal fistula?

Do you consider diversion colostomy, or abdominoperineal resection up front?

4 Answers available

Do you ever treat patients with rectal or anal cancer with IMRT in the prone position?

1 Answer available

What is the best treatment approach for locally advanced (T3+ and/or N+) rectal cancer status post low anterior resection in a patient who has a remote history of seed implant for low risk prostate cancer?

What are your thoughts on dose, avoidance structures, re-tx risk, etc?

1 Answer available

Should inoperable squamous cell carcinoma of the esophagus be treated to doses > 60 Gy?

Should the recent publication of Chen et al. dose escalation study for inoperable SCC esophageal cancer patients treated with CCRT, showing an 8% 5-ye...

2 Answers available

How do you manage grade 3 dermatitis during chemoradiation therapy for anal cancer?

Aquaphor, barrier cream, sitz baths, domboro, silvadene, foam dressings?

8 Answers available

In what situations do you recommend preoperative chemoradiation for gastric cancer?

1 Answer available

Should patients who received pelvic radiation get colonoscopy screenings more often than what is recommended for the general population?

In view of higher risks of rectal cancer after pelvic radiation, is more frequent screening warranted?

1 Answer available

Do you routinely use any type of motion management or breathing techniques when treating a lower esophageal cancer?

3 Answers available

How do you manage gastroesophageal junction cancer after resection with a positive circumferential surgical margin when no neoadjuvant treatment has been given?

1 Answer available

Would you recommend adjuvant chemoradiation for T1N0 gastric adenocarcinoma status post R0 resection but no D2 lymph node dissection?

Does the lack of D2 dissection automatically necessitate adjuvant chemoradiation therapy (ie <5 LN obtained)? Would the presence of high risk facto...

1 Answer available

Would you use standard neoadjuvant chemoradiation for a patient with advanced rectal cancer and a history of previous pelvic RT for another cancer?

For a patient with cT3-4N0 rectal cancer, does the dose of the previous RT affect your decision making (for example, 45 Gy to the pelvis with boo...

2 Answers available

When would you consider initial induction chemotherapy (e.g. FOLFOX) followed by neoadjuvant chemoradiation, over neoadjuvant chemoradiation alone, in patients with locally advanced rectal cancer?

2 Answers available

How do you manage unresctable thoracic esophageal cancer invading the trachea?

What chemotherapy and radiation doses/fractionation would you use once the airway has been stabilized to provide reasonably safe and effective palliat...

1 Answer available

What is your preferred palliative regimen for pancreatic cancer with pain related to celiac plexus involvement?

Do you consider palliative SBRT 25Gy in 5 fractions? I often find that these patients are in severe pain and my typical regimen is 30 Gy in 10 fractio...

2 Answers available

When treating adenocarinoma of the pancreas to 75 Gy in 25 fractions, what dose constraints do you use for small bowel, large bowel, and stomach?

What are your fields? Do you treat nodes electively?

1 Answer available

When treating an inoperable patient with squamous cell carcinoma of the thoracic esophagus, do you ever dose escalate beyond 50.4Gy?

What doses do you use?

1 Answer available

When treating a patient with anal cancer with a vaginal dilator, do you routinely simulate the patient with and without the dilator in place?

How often do patients become unable to tolerate the dilator during the treatment course secondary to discomfort related to acute toxicity?

3 Answers available

How would you treat a p16+ small cell neuroendocine tumor of the anal canal with or without metastatic inguinal lymph node metastasis?

Would the radiation dose and fields be the same as for squamous cell carcinoma? What chemotherapy would you recommend?

2 Answers available

When treating recurrent rectal cancer with re-irradiation using accelerated hyperfractionation (39-45 Gy at 1.2 or 1.5 Gy BID), what normal tissue constraints would you recommend for the bladder and bowel?

1 Answer available

What dose of radiation do you use for neoadjuvant chemoradiation in esophageal cancer?

The CROSS trial showed a survival benefit with 4140cGy and concurrent carbo/taxol, but I was always trained to treat to 5040cGy. Is anyone de-escalati...

5 Answers available

In a thin patient with anal cancer, do you use bolus over the inguinal nodal volume when treating with an IMRT technique?

2 Answers available

What positioning and immobilization technqiues do you use for anal canal carcinoma radiotherapy in the era of IMRT?

On the heels of the discussions regarding skin toxicity prophylaxis and treatment, I am interested in your thoughts and current practice regarding pat...

1 Answer available

What dose do you typically prescribe to the primary tumor for definitive treatment of squamous cell carcinoma of the anal canal (given concurrently with chemotherapy)?

Do you have different preferences based on T-stage?

6 Answers available

How would you treat an early-stage gastric adenocarcinoma in a patient who is medically inoperable and not fit enough for chemotherapy?

Is there such thing a definitive radiotherapy in this setting, or would this be a purely palliative approach? If you would treat, what would your targ...

3 Answers available

What approach have you found works best in treating persistent acute radiation proctitis in patients undergoing pelvic EBRT?

2 Answers available

How do you manage patients with history of multiple perianal condylomas who develop focal high grade squamous intraepithelial lesions in the anal margin?

What would be your preferred management, surgical resection or radiation? If radiation is contemplated, what dose would be appropriate and would HPV s...

2 Answers available

What factors determine the choice of treatment in the management of intermediate (BCLC stage B) hepatocellular carcinoma?

What features would help you decide between TACE vs. TARE vs. external beam radiation therapy?

1 Answer available

What are your preferred target doses for bulky T4 rectal adenocarcinomas with extensive GU and anal sphincter involvement as well as common illiac and inguinal adenopathy, as part of total neoadjuvant therapy when future APR is planned?

In particular, many guidelines suggest a max point dose of 50Gy for small bowel but in cases of extensive disease how do you reconcile loops of bowel ...

1 Answer available

In patients undergoing pre-operative chemoradiation for rectal adenocarcinoma with clinically positive pelvic sidewall nodes that may not be surgically accessible, do you boost these nodes above 50.4 Gy?

If so, what dose do you boost these nodes to?

1 Answer available

What volumes and prescription doses do you use when treating patients with unresectable cholangiocarcinoma?

Do you electively treat nodes and how does your approach change with intra- or extra-hepatic primaries?

1 Answer available

In locally advanced rectal cancer treated with total neoadjuvant therapy, do you adjust boost volumes to only include post-chemo gross disease/nodes plus a margin?

1 Answer available

What types of sexual side effects do you discuss with men undergoing radiation therapy for rectal and/or anal cancer?

Is there a risk for anejaculation?

2 Answers available

Can you skip elective inguinal treatment in PET negative squamous cell carcinoma of anal canal?

2 Answers available

Which patients would you offer a watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer?

Based on the UK OnCoRe matched cohort analysis, would you offer a watch-and-wait approach off protocol or are you uncomfortable treatin...

5 Answers available

How would you approach treatment in recurrent, localized rectal mucinous adenocarcinoma?

Would you consider repeating neoadjuvant chemo/RT? Does this, occurring in the context of Lynch Syndrome, change the treatment approach?

1 Answer available

How do you manage early stage anal or anal margin cancer that is locally excised with negative but close margins when going back for wider margins would require an APR?

4 Answers available

How would you treat a synchronous anal and oropharyngeal squamous cell carcinoma?

If the oropharyngeal cancer is operable (ex T1N1), would would your preference be upfront surgery? Would you use chemoradiation therapy to bo...

1 Answer available

How would you approach a low-lying rectal cancer wtih para-aortic lymphadenopathy?

Would you recommend only chemotherapy or would you offer chemotherapy followed by restaging and possible definitive CRT and surgery?

3 Answers available

How do you manage a patient with a 3.5 cm squamous cell carcinoma of the perianus (with no involvement of the anal canal) with a positive inguinal node?

Are the treatment volumes the same as those for squamous cell carcinoma of the anal canal?

1 Answer available

When treating younger men with anal cancer do you consider dose to the prostate?

Given risk of secondary malignancies do you make an effort to avoid/spare the prostate or give any specific dose constraints when treating young men w...

1 Answer available

How would you manage a patient with a very large adenocarcinoma of the rectum (10 cm) that extends to the anal verge with positive peri-rectal and inguinal lymph nodes, but no distant organ involvement?

Is this patient considered to have metastatic disease? Should definitive surgery be considered?

1 Answer available

How would you manage a patient who presented with synchronous squamous cell carcinoma of the anus (cT2N0) and adenocarcinoma of the rectum (cT3N0) at 7cm from the anal verge?

1 Answer available

For rectal cancer with solitary liver metastasis, do you recommend neoadjuvant chemoradiation?

Are these patients better candidates for preop chemotherapy alone?

2 Answers available

Would you consider PCI for a patient with neuroendocrine carcinoma of the esophagus?

1 Answer available

What are your treatment volumes for patients with gastric cancer receiving adjuvant chemoRT for a positive margin following gastrectomy and D2 nodal dissection?

Will you treat only the anastamosis and remnant stomach without elective nodal RT, or will you include elective nodal RT in your treatment fields, ass...

1 Answer available

Would you ever recommend radiation alone for a T1N0 anal cancer?

1 Answer available

What is your treatment algorithm for solitary hepatocellular carcinoma, 3-5 cm, non-operative candidate but Child-Turcotte Pugh A/B?

Do you recommend TACE, RFA, radioembolization, systemic therapy or SBRT? What if the size is >5 cm?

1 Answer available

How do you treat localized esophageal carcinoma in patients who are unwilling or unable to undergo chemotherapy or surgery?

If a patient is unable or unwillling to undergo dual or tri-modality therapy with chemotherapy or surgery, would you use a palliative radiation treatm...

1 Answer available

When would you add an extra radiation dose to compensate for treatment breaks?

Apart from H&N SCC, are there times where adding an extra dose of radiation due to a tx break is appropriate? Is there a decent equatio...

1 Answer available

What dose fractionation would you recommend for large (>5 cm) perianal Bowen's disease (squamous cell CIS)?

1 Answer available

What dose constraint(s) would you use for a patient with a pelvic kidney transplant getting pelvic RT?

1 Answer available

Is extensive abutment of the duodenum without invasion a contraindication to SBRT for pancreatic tumors?

If so, how do you quantify this when making a decision about who may or may not be a candidate for SBRT?

1 Answer available

What methods do you use to decrease genital skin reaction when delivering pelvic radiation to patients in the prone position?

1 Answer available

How would you manage a patient with synchronous locally advanced H&N (p16+) and locally advanced rectal adenocarcinoma?

If treating the H&N first, would you anticipate some effect of chemo on the rectal cancer? Would you include 5FU in the H&N chemo for be...

2 Answers available

Would you consider post operative boost radiation for positive margin in a patient with rectal cancer who underwent short course RT(25 Gy in 5 fractions) prior to TME?

What fractionation would you use?

2 Answers available

Would you consider induction chemotherapy prior to starting chemoradiation therapy in squamous cell carcinoma of the esophagus?

If the patient has large, bulky nodes would you consider starting after chemotherapy for cytoreduction? Or otherwise consider replanning mid-treatment...

2 Answers available

What treatment do you recommend for patients with Siewert III gastroesophageal junction cancer with periesophageal or mediastinal lymph node involvement beyond what is considered regional for gastric cancer?

Would you recommend chemoradiation therapy or chemotherapy upfront?

1 Answer available

How would you manage an inguinal-only recurrence of a previously treated low lying rectal cancer?

Any role for surgery? What radiation volumes would be used?

2 Answers available

How do you manage urgency and frequency of bowel movements secondary to radiation proctitis?

1 Answer available

Which chemotherapy regimen do you prefer for concurrent treatment with radiation therapy for anal squamous cell carcinoma?

5FU/mitomycin C or 5FU/cisplatin? Is there any benefit of cisplatin in terms of skin toxicity?

2 Answers available

How would you treat an excised T1N0M0 anal canal well-differentiated squamous cell carcinoma with positive microscopic margin?

Do you recommend 5FU/mitomycin chemoradiotherapy or radiotherapy alone? What evidence is there for efficacy and toxicity differences between the two ...

3 Answers available

Do you prefer to treat patients prone (on a belly board) or supine when treating rectal cancers?

Is there any evidence to show that treating with a bellyboard is preferred?

3 Answers available

How would you manage locally advanced anal cancer patients with PET positive para-aortic lymph nodes?

2 Answers available

Does external iliac coverage, such as in a T4 primary, justify IMRT for rectal cancer?

2 Answers available

Do you offer adjuvant radiation therapy for patients with hepatocellular carcinoma status post partial hepatectomy with positive parenchymal margins?

What dose and volumes would you use?

2 Answers available

Would you consider observation instead of a Whipple in a borderline resectable pancreatic cancer patient treated with neoadj CRT who has a radiographic CR?

If the patient received neoadjuvant FOLFOX for 4 cycles then 50.4 Gy with concurrent capecitabine, is that enough treatment to omit surgery?

1 Answer available

How would you manage a patient with distal rectal adenocarcinoma involving the anal canal and a single non-bulky inguinal nodal metastasis?

Is curative intent surgery off the table?

4 Answers available

Would you give post-operative radiation therapy and/or chemotherapy after an APR for anal cancer if inguinal lymph nodes were involved but margins were negative?

Surgery showed 1/5 and 1/4 LNs involved in the groins. What areas would you cover and with what corresponding doses?

1 Answer available

Would you boost a positive margin (R1 resection or R2 resection) in a GEJ esophageal carcinoma that completed neoadjuvant chemoradiation?

What if the patient was not a candidate for additional chemotherapy? Would your answer change if the patient received the CROSS regimen with <...

1 Answer available

Has SBRT shown to improve OS or PFS in patients with localized pancreatic cancer who are not a eligible for surgery due to other comorbidities?

2 Answers available

How do you treat anal adenocarcinoma?

Is the approach chemoradiotherapy (Mitomycin-5FU) as for squamous carcinoma with surgery only for salvage or do you always perform surgery after neo-a...

1 Answer available

Can short course radiation therapy (5 Gy x 5 fractions) be given for low lying rectal tumors, near the sphincter but not involving it?

Is there a risk of increased sphincter tone issues in these patients?

2 Answers available

What SBRT dose and tissue constraints would you choose for a presacral rectal recurrence status post preoperative chemoradiation to 50.4 Gy followed by surgical resection in a patient who is not a candidate for surgical re-resection?

1 Answer available

For liver metastases, what criteria do you use to decide between SBRT vs Y90?

Is there a benefit of SBRT over Y90 or vice versa?

1 Answer available

Would irreversible elctroporation (IRE) performed at the time of Whipple affect your plans or dose for radiation in the setting of adjuvant treatment for pancreatic adenocarcinoma?

1 Answer available

What is the appropriate follow up after chemoradiotherapy for patients with anal SCC?

Is obtaining serial MRIs or other imaging appropriate?

1 Answer available

Would you consider maintenance therapy for patients who achieve complete response after palliative chemoradiation for metastatic distal esophageal adenocarcinoma?

If so, what regimen would you consider?

1 Answer available

What is the role of radiation in regionally recurrent gastric cancer?

In a patient who received upfront surgery and chemotherapy who later recurred in the regional nodes, s/p lymphadenectomy, would you offer RT? If...

1 Answer available

How would you approach isolated inguinal lymph node squamous cell carcinoma of occult primary?

If workup is negative for a primary lesion, would you consider prophylaxis of potential primary sites (anus/vulva?), and would you treat bilateral ing...

1 Answer available

What is the preferred palliative regimen for elderly patients with rectal cancer who elect to forego surgery?

Is concurrent chemoradiation reasonable or excessive in a patient with life expectancy <5 yrs? Should the standard be 5 Gy x 5, and will this provi...

2 Answers available

What target volumes do you use for rectosigmoid / very superior rectal cancers?

Does it ever differ from a standard rectal field? For example, do you always treat the entire rectum, mesorectum, and entire length of internal iliac ...

2 Answers available

What techniques do you use to minimize gas artifacts on cone beam CT when treating upper abdominal lesions?

Antacids? Anti-motlity agents? Dietary changes? Combination?

1 Answer available

In what situations do you recommend adjuvant radiotherapy for colon cancer?

How do you deliver it safely? Even when there is adherence to other organs (T4) or positive margins, I'm hesitant to offer RT because the volumes are ...

2 Answers available

What cumulative dose constraints would you use for the normal liver when repeating SBRT for liver metastases with a longer time interval (i.e. 2-3 years)?

Do you factor in the time interval when deciding cumulative dose constraints?

1 Answer available

Would you consider BID treatment for a patient with a pelvic SCC (e.g. cervix or anal) if a significant amount of treatment days have been missed?

For example, a patient with cervical or anal SCC who has missed many treatments due to side effects, low blood counts, hospitalizations, or non-compli...

1 Answer available

When is radiation indicated in the treatment of perianal paget's disease?

A nuimber of options for treatment but not a lot of great data for this rare disease.

1 Answer available

Do you treat inguinal lymph nodes for rectal cancers involving the anal canal?

The RTOG contouring atlas doesn't give a consensus on this issue.

4 Answers available

How do you do immobilization for liver SBRT?

What method provides the best reproducibility? Abdominal compression? Inhale breath hold? Exhale breath hold?

1 Answer available

How do you manage a patient with gastric/GE junction carcinoma who has positive lymph nodes at resection after neoadjuvant chemotherapy?

If you would elect for adjuvant therapy, which study helps guide your choice of regimen?

1 Answer available

How would you manage dysphagia and odynophagia in an otherwise healthy patient with newly diagnosed metastatic esophageal cancer with a large primary in the mid to distal esophagus?

Would you send the patient for a stent or do palliative RT?

4 Answers available

When giving hypofractionated ablative doses of radiation for cholangiocarcinoma, do you give concurrent Xeloda or hold chemo during radiation?

http://ascopubs.org/doi/full/10.1200/JCO.2015.64.2710

1 Answer available

Would you recommend repeat radiation therapy for a painful perineal recurrence in a patient who failed definitive CRT, and recurred again after salvage abdominoperineal resection (APR)?

What would be the RT dose and what percentages would you quote for toxicities? Would you recommend consideration of surgery instead?

2 Answers available

Would you treat rectal squamous cell carcinoma the same as rectal adenocarcinoma, stage for stage?

Any adjustments in terms of elective nodal coverage?

2 Answers available

When is it appropriate to recommend a diverting colostomy for treatment of anal cancer or low lying rectal cancer?

Fecal incontinence can be one indication. What are others?

2 Answers available

What is the appropriate role for radiation therapy in patients with HCC or intrahepatic cholangiocarcinoma who are transplant candidates?

Should radiation be offered as a bridge to transplant? Should this depend on whether SBRT is feasible (i.e. is fractionated IMRT an appropriate option...

1 Answer available

What is the appropriate dose and volume for adjuvant treatment of a sigmoid colon adenocarcinoma adherent to the L5 vertebral body with a positive radial margin?

2 Answers available

Do you offer adjuvant radiotherapy for pancreatic adenocarcinoma following surgical resection?

Given lack of strong evidence supporting the benefits of adjvuant RT in resected pancreatic adenocarcinoma (with results of the ongoing RTOG 0848 unav...

1 Answer available

Do you ever offer repeat radiation for hepatobiliary cancers in cases of local recurrence after definitive external beam or SBRT?

If so, what constraints would you use for central biliary and other normal structures and what dose/fractionation would you use?

1 Answer available

Can pre-op chemoRT be used to potentially downstage an early stage rectal cancer (i.e. T2 N0) for a sphincter sparing operation?

4 Answers available

In a male patient with a single inguinal node containing SCC, with no identifiable anal or penile lesions, what areas would you cover and to what dose?

Would you treat the node alone, unilateral/bilateral inguinal nodal basins, or cover any possible primary locations such as the anal mucosa?

1 Answer available

For patients receiving concurrent chemoradiation for anal cancer, what is your ANC threshold for holding radiation or switching to a boost plan to limit myelotoxicity?

1 Answer available

Have the results of LAP07 caused your institution to pursue more aggressive systemic therapy before radiotherapy in the treatment of pancreatic cancer?

Is better systemic control needed to make radiation therapy beneficial?

1 Answer available

When treating prostate or other pelvic malignancies, what dose constraints do you use for the sigmoid colon?

Do you use the same constraints that you would for the rectum? Or perhaps employ a lower dose limit, such as not exceeding 65Gy to a small volume of t...

1 Answer available

Would you recommend an inguinal node dissection as part of definitive treatment for adenocarcinoma of the anus with suspicious inguinal nodes?

What about bulky nodal disease?

1 Answer available

How do you treat hiccups in cancer patients?

Does your management differ if the hiccups are felt to be related to chemotherapy as opposed to the disease itself?

1 Answer available

What dose constraint, if any, do you use for the diaphragm when treating liver or lung tumors with SBRT?

Have you ever seen toxicity related to diaphragm dose with conventional fractionation?

4 Answers available

In patients with newly diagnosed cervical esophageal cancer with limited metastatic disease, do you treat the primary with chemoradiation?

1 Answer available

What treatment volume is appropriate when treating postoperatively for esophageal carcinoma?

In what situation, if ever, do you include mediastinal nodes?

1 Answer available

How do you optimize nutrition for patients experiencing dysphagia while undergoing chemoradiation therapy for esophageal cancer?

Is there a preferred method and should any of the following be avoided: esophageal stent, nasogastric tube, PEG, J-tube, or TPN?

1 Answer available

How do you approach bowel constraints in the setting of reirradiation?

Do you assume some recovery since the prior course of RT? If so, how much over what time period?

1 Answer available

In light of the recently published LAP07 trial, what is the role of radiation in unresectable pancreatic cancer?

In LAP07's second randomization (capecitabine+54 Gy vs maintenance gemcitabine +/- erlotinib), 60% of unresectable pancreatic cancer patients who did ...

3 Answers available

What GTV to CTV margin do you typically use for the primary lesion in anal cancer?

RTOG 0529 guidelines were 2.5cm margin from GTVA to CTVA (except bone or air), do you still follow this practice?

1 Answer available

How would you treat locoregionally recurrent anal CA?

If a patient developed locoregional recurrence after initial chemoradiation, would resection of known disease followed by observation be preferred?

1 Answer available

Are there situations in which elective nodal volumes may be reduced for T1/T2N0 anal SCC?

Is inguinal coverage always required?

3 Answers available

Do you recommend neoadjuvant chemotherapy or induction chemo + chemoRT for borderline resectable pancreatic cancer?

With the current data, I'm struggling to justify addition of radiation for potentially resectable disease. If in favor of RT, do you recommend s...

3 Answers available

For esophageal and gastroesophageal junction cancers, which lymph nodes are metastatic versus regional?

Specifically, are hilar nodes metastatic?

1 Answer available

Is acute pancreatitis a contraindication to radiotherapy for patients with pancreatic cancer?

Does treatment of the pancreas with radiotherapy during an episode of acute pancreatitis increase the risk of acute and late side effects? Should one ...

2 Answers available

Given the significant risk of recurrence after chemoradiation for locally advanced anal carcinoma, should resection be considered (with or without neoadjuvant treatment) in select cases?

At other sites we consider locally advanced disease and high risk of recurrence a contraindication for organ preservation. Would surgery improve likel...

1 Answer available

How do you treat anal margin tumors?

Per NCCN, only well-differentiated T1 lesions (with 1cm surgical margins) should be excised (with no other treatment). Do you follow this at your inst...

1 Answer available

Is it safe and appropriate to palliatively treat abdominal or thoracic tumors with concurrent chemotherapy when using fractions of 250-300 cGy?

For example, there is a retrospective series out of MD Anderson (Kim, Acta Oncologica 2008) wherein 37 patients with gastric cancer were treated with ...

2 Answers available

What is the optimal dose fractionation for treating liver metastases in the central liver causing obstruction of biliary flow?

Will higher doses per fraction increase the risk of fibrosis and cause permanent impediment to biliary flow?

1 Answer available

Are there any special considerations when treating a patient with anal cancer who has poorly managed HIV/AIDS?

2 Answers available

Is there an advantage in treating with a SIB (simultaneous integrated boost) over sequential boost for anal cancer?

1 Answer available

In what situations, if any, do you offer postoperative radiation or chemoradiation for patients with squamous cell carcinoma of the esophagus?

Would your recommendation change if the histology was adenocarcinoma (excluding GE junction tumors)?

2 Answers available

How do you interpret the results of the ACT II trial in terms of the choice between cisplatin and mitomycin in the treatment of anal cancers?

Reference: https://www.ncbi.nlm.nih.gov/pubmed/23578724

1 Answer available

Do you base liver SBRT dose fractionation on size, volume, or proximity of normal tissue?

For example, would you use a cutoff such as PTV of 25cc, or 4cm diameter, or simply use nearby normal tissue constraints to alter your fractionation f...

3 Answers available

When treating borderline resectable pancreatic adenocarcinoma patients with neoadjuvant chemoradiation, do you treat the elective nodal regions or the primary alone?

Is your approach similar in unresectable disease? Is there evidence to support one approach over the other?

2 Answers available

In a patient with a small cell of the esophagus in which trimodality therapy is planned what dose of preoperative radiation would you use and would you utilize BID fractionation?

1 Answer available

How do you approach disease monitoring in patients with localized rectal cancer who have received treatment with chemoradiation?

Is MRI being considered the primary mode of imaging in multidisciplinary tumor boards, especially in light of the results of the MERCURY trial (JCO 20...

1 Answer available

In a patient with a large condyloma adjacent to a squamous cell carcinoma of the anal canal being treated with chemoradiation how would you incorporate the condyloma in the target volume if it is PET negative and would it receive a different dose?

2 Answers available

Do you electively cover the celiac axis in a patient with node negative middle third to distal, and GEJ esophageal carcinoma?

What factors do you use in deciding whether or not to electively cover the celiac axis?

1 Answer available

How do you manage unresectable esophageal cancer involving both the thoracic esophagus and GE junction?

In the case of multiple skip lesions in the thoracic esophagus and GE junction, the PTV may encompass nearly the entire esophagus, including the supra...

3 Answers available

What maximum volume (in cc's) of small bowel would you allow to receive 45 Gy in a patient with node positive squamous cell carcinoma of the anal canal receiving concurrent chemoradiation with 5-FU/MMC being treated with IMRT?

What if a large portion of small bowel is located within PTV45?

1 Answer available

When treating a high grade neuroendocrine tumor of the rectum with involved pelvic lymph nodes, do you use the same approach (dose, fractionation, concurrent chemotherapies) as you would for a small cell lung cancer?

Would you use platinum/etoposide concurrent with radiation or would you opt for platinum only during radiation? Would you use BID fractionation...

1 Answer available

Should capecitabine be administered at a specific time prior to RT in pre-op chemoradiation treatment for rectal cancer?

Would taking the drug at a specific time point prior to their radiation appointment time to maximize blood levels of the drug be clinically beneficial...

1 Answer available

Is it feasible to treat central liver tumors +/- portal vein thrombus with SBRT while minding central hepatobiliary tract constraints?

The Stanford report (Osmundson, IJROBP 2015) on central hepatobiliary tract toxicity recommended dose constraints to the cHBT that would limit dose to...

2 Answers available

Would you advocate for sphincter preserving chemoradiation therapy for a patient with a diagnosis of anal canal carcinoma who has previously been treated with pelvic radiation such as EBRT or brachytherapy?

How would your radiation treatment approach change in terms of dose and target definition? Would the time interval between diagnosis affect the optio...

2 Answers available

Is there any role for adjuvant radiation for a low grade, intraductal papillary mucinous neoplasm (IPMN) of the pancreas after resection with a positive pancreatic margin?

1 Answer available

When treating locally advanced/borderline resectable pancreatic cancer with SBRT, what are the typical duodenal dose constraints you utilize?

2 Answers available

What is your typical target/field when treating a patient with 5 Gy x 5 fractions pre-operatively for rectal cancer?

Do you target the whole pelvis or a smaller "boost-like" field?

2 Answers available

What would you include in the radiation field for a patient with T2 N0 M0 adenocarcinoma of the distal 1/3 of the esophagus?

In a patient who is not a surgical candidate and has a negative PET/CT and EUS, would you include celiac lymph nodes in the radiation field?

1 Answer available

Is there evidence to support routine use of adjuvant chemotherapy for resected rectal cancer treated with pre-operative chemoradiation?

The NCCN seems to make its recommendation based on extrapolation from colon cancer, but those patients are not treated with pre-op chemoRT.

1 Answer available

Is it acceptable for a medical oncologist to use Xeloda in place of 5FU when treating GI sites other than rectal?

Specifically - anus, pancreas, gastric?

2 Answers available

Is it appropriate to use SBRT on unresectable pancreatic tumors invading the duodenum?

Do you use any age limit to determine whether pancreatic SBRT is appropriate?

1 Answer available

Should patients with anal canal SCC undergo an FNA biopsy of any palpable inguinal LN that is also FDG avid on PET/CT or should these nodes be assumed to be positive and treated to a higher dose?

How do you manage a patient a with a PET positive inguinal lymph node who has a typical anal cancer? If a biopsy is done and it is negative, is it is ...

1 Answer available

What adjuvant therapy recommendations would you make for a patient with pT3N0M0 duodenal cancer?

In a case with negative margins, would you consider chemotherapy alone or sequence with chemoradiation?

1 Answer available

Is chemoradiation the preferred treatment for T2 SCC of the anal canal in a patient with IBD?

Does the presense of ulcerative colitis, now in remission, affect your dose and fields?

1 Answer available

How do you use a 4D CT to account for hepatocellular carcinoma tumor motion?

When planning SBRT cases for primary liver cancers, it is very difficult to see the tumor on the non-contrast 4D scan. How do you use information from...

2 Answers available

Is there an "ideal" method for abdominal motion control when treating upper abdomen malignancies?

In my training, we used an abdominal compression paddle, but in my current practice, my physicist says that we cannot treat through multiple parts of ...

1 Answer available

Are special precautions necessary for esophageal cancer with tracheal invasion prior to chemoradiation?

Are there any precautions to prevent formation of a TE fistula?

1 Answer available

What is your preferred dose for definitive radiation of squamous cell cancer of the thoracic esophagus that will be combined with chemothererapy?

Would your approach change if the histology were adenocarcinoma?

1 Answer available

How do you manage patients with low-lying rectal adenocarcinoma who refuse surgery?

Should these patients be managed with high dose chemoradiation similar to the Danish study (Lancet in July 2015)? To what dose would you take the prim...

1 Answer available

For patient with primary liver carcinoma, is prior radioembolization with Yttrium-90 microspheres a contra-indication (relative or absolute) to external beam radiation therapy with either stereotactic body radiation therapy (SBRT) or proton beam therapy ?

2 Answers available

Would you treat the inguinal nodes in a patient who had an adenocarcinoma excised from the anal canal?

In a lesion <2.5 cm from anal verge arising in a tubulovillous adenoma, does the data from Taylor, et. al. Red Journal 2001 apply?

2 Answers available

What is the evidence that there is a benefit to giving doses higher than 3060 cGy-3600 cGy in the elective treatment of uninvolved lymph nodes in the treatment of SCC of anal canal with chemoradiation?

3 Answers available

How do you treat locally advanced, operable, Siewert 3 GE junction adenocarcinomas?

1 Answer available

Is liver radiotherapy contraindicated in patients with Child-Pugh C liver function?

Would you avoid any RT in these patients, including palliation for a portal vein thrombus? Or would you consider a short course of RT (like 20Gy/5fx)?

4 Answers available

For elderly patients with locally advanced rectal cancer who are not candidates for surgery or chemotherapy, what would be an appropriate palliative regimen?

1 Answer available

Do you recommend adjuvant chemoradiation for T2N0 gastric adenocarcinoma?

In a patient with an R0 resection, would you routinely recommend postop chemoradiation, since these patients were included in the MacDo...

1 Answer available

When treating pancreatic cancer with adjuvant chemoradiation, do you treat the initial field to 50 Gy, as per RTOG 0848, or to 45 Gy?

For cases with positive margins, do you boost to 54 Gy? If so, do you boost the entire tumor bed or only the area of the positive margin?

2 Answers available

In what setting do you omit adjuvant radiation therapy in a T3N0 rectal cancer?

The NCCN guidelines categorically recommend adjuvant XRT for a cT1-2N0 rectal adenocarcinoma upstaged to a pT3N0, yet there are multipl...

1 Answer available

What dose and upper field border would you use following transanal excision for rectal cancer found to be T2 by final pathology but without LVSI or perineural invasion?

Should standard post operative radiation fields be used, treating up to the L5-S1 interspace? Or is it acceptable to treat a lower field, for ins...

1 Answer available

Following transanal excision with positive margins for for T1 or T2 rectal cancer, is it more appropriate to proceed with APR or attempt sphincter preservation with RT/Chemo?

If RT/chemo is preferred, what is an acceptable final boost dose?

1 Answer available

What is the appropriate treatment for a low lying rectal cancer in the setting of prior definitive prostate IMRT?

Fore example for a T3N0 rectal cancer on EUS?

1 Answer available

Do you treat rectosigmoid/upper rectal cancers with neoadjuvant chemoradiation?

The German trial included patients with tumors up to 16cm from the anal verge, while the Swedish trial update found no local control benefit for tumor...

4 Answers available

What dose and volume would be recommended for a medically inoperable patient with a T4 Rectal adenocarcinoma?

Would you boost to >54Gy? 60Gy? Is there relevant literature/evidence for supporting a higher dose?

1 Answer available

When treating rectal cancer with neoadjuvant chemoRT, is it appropriate to employ IMRT planning, rather than 3D conformal, for all cases, or should IMRT be reserved for special circumstances?

1 Answer available

Is it possible to palliate presacral recurrences of rectal cancer in patients who previously received neoadjuvant chemoradiation to the rectum?

In the past, I haven't seen great results in palliating the presacral area. The pain is excruciating for many patients. Is there an effective option f...

1 Answer available

For a GE junction tumor with a lymph node distant from the primary site, would the treatment volume be contiguous?

I.e. Would you treat most of the normal esophagus to include a mediastinal lymph node?

1 Answer available

How do you manage squamous cell carcinoma in situ of the anus?

While the Nigro/Wayne state regimen consisting of Mito C & 5FU is well stablished for squamous cell carcinoma of the anus/perianal tissue, a...

1 Answer available

For a patient who has undergone preoperative chemoradiation to 50Gy for locally advanced rectal cancer followed by LAR or APR, would you treat a positive margin with radiation therapy?

If so, what dose?

2 Answers available

How do you contour distal esophageal cancer in the postop setting after Ivor-Lewis pT3N3 (perigastric and periesophageal LN)?

What regional lymph nodes do you include perigastric, portahepatic, periesophageal, celiac, splenic, pancreaticoduodenal, sup. mesenteric, paraesophag...

1 Answer available

Has pelvic MRI replaced EUS as the standard of care for rectal cancer staging?

Are there any indications to choose one over the other?

1 Answer available

What is the likelihood of a successful pregnancy following pelvic irradiation?

How should we counsel young women who are receiving treatment for GI/GYN malignancies?

1 Answer available

How do you treat synchronous rectal cancer and prostate cancer?

I have a healthy 70+ year old man recently diagnosed with cT3N1M0 rectal adenoCA and GS 3+4=7 prostate cancer in 1/6 cores with a PSA of 25.

2 Answers available

Which regimen is better for gastric adenocarcinoma- neoadjuvant chemotherapy or adjuvant chemoradiation?

Is there a consensus on the MAGIC v. MacDonald debate?

2 Answers available

Is there a role for PET/CT in pancreatic cancer staging or treatment planning?

I recently had a patient with unresectable disease ask for a PET before starting RT but I’m not sure there is a benefit.

1 Answer available

How do you justify adjuvant radiotherapy in pancreatic cancer?

I can't convince the surgeons to refer their patients for adjuvant RT because the prospective data is messy and doesn’t seem to indicate a benef...

1 Answer available

Should I use PET/CT for GE junction treatment planning?

We use PET for esophageal, but not gastric cancer. GE junction seems like a grey area.

1 Answer available

Do you stage and treat GE junction tumors like gastric or esophageal cancer?

1 Answer available

Do you ever give postoperative chemoradiation in patients who underwent preoperative chemotherapy for gastric adencocarcinoma?

1 Answer available

How do you control for organ motion when treating pancreatic cancer?

What techniques work best?

2 Answers available

Papers discussed in this category

N. Engl. J. Med., 2012-05-31

Preoperative chemoradiotherapy for esophageal or junctional cancer.

Lancet Oncol., 2015-09-01

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Cancer, 2007 Nov 15

Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.

J Clin Oncol, 2008 Jul 20

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.

J Clin Oncol, 2008 Jul 20

Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

Cancer, 1987 Jun 15

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.

Ann Surg, 2007 Nov

Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

N Engl J Med, 2006 Jul 6

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

N. Engl. J. Med., 2001-09-06

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

BMC Cancer, 2015-07-21

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

J. Clin. Oncol., 2009-02-20

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Nat Clin Pract Oncol, 2005 May

Multidisciplinary treatment of synchronous primary rectal and prostate cancers.

Pract Radiat Oncol, 2012 Oct-Dec

Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer.

Urology, 1999-10-01

Combined radical retropubic prostatectomy and rectal resection.

Urology, 2001-04-01

External beam radiotherapy for synchronous rectal and prostatic tumors.

Int J Colorectal Dis, 2012-11-01

Management of synchronous rectal and prostate cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2001-11-01

Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal.

Radiat Oncol, 2014-12-23

Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?

Lancet, 2009-03-07

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

J. Clin. Oncol., 2012-06-01

Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Br J Surg, 2006-10-01

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.

J. Clin. Oncol., 2012-11-01

Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Int J Radiat Oncol Biol Phys, 2014 Mar 15

Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.

Ann. Surg. Oncol., 2017 May 30

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

Ann. Oncol., 2019 Jun 13

Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study.

Ann. Surg., 2007-11-01

The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Int. J. Radiat. Oncol. Biol. Phys., 2008-02-01

Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.

Cancer, 1983-05-15

Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal.

Cancer, 2010 Feb 15

Long-term quality of life after radiotherapy for the treatment of anal cancer.

Int J Radiat Oncol Biol Phys, 2012 Nov 12

RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal.

Int J Radiat Oncol Biol Phys, 2007 Feb 1

Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma.

J Clin Oncol, 2004 Aug 15

Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.

J Cancer Res Ther, 2011 Oct-Dec

Stereotactic body radiotherapy for the treatment of presacral recurrences from rectal cancers.

Cancer, 2015 Apr 1

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

JAMA, 2012 Jul 11

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

JAMA, 2008 Mar 5

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.

J Clin Oncol, 2011 Aug 1

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Int J Radiat Oncol Biol Phys, 2011 Sep 1

Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

Am J Clin Oncol, 2011 Feb

Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.

Int J Radiat Oncol Biol Phys, 2013 Dec 1

Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

JAMA, 2007 Jan 17

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

J Can Assoc Radiol, 1975-09-01

The 1975 Gordon Richards Memorial Lecture. Is the Miles operation really necessary for the treatment of rectal cancer?

Int. J. Radiat. Oncol. Biol. Phys., 1995-01-15

Adenocarcinoma of the rectum treated by radical external radiation therapy.

J Clin Oncol, 2004 May 15

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Dis. Colon Rectum, 2008-08-01

Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

J Clin Oncol, 2012 Jul 1

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

J Thorac Oncol, 2006 Mar

Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience.

J Clin Oncol, 2002 Mar 1

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

J Clin Oncol, 2007 Apr 1

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

J Clin Oncol, 2005 Apr 1

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Curr Oncol Rep, 2019 Apr 04

Cervical Esophageal Cancers: Challenges and Opportunities.

Int. J. Radiat. Oncol. Biol. Phys., 2016 Sep 03

Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Jan 09

Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.

Dis. Esophagus,

Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis.

J Clin Oncol, 2016 Jan 20

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.

Technol. Cancer Res. Treat., 2014-06-01

The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiotherapy.

Int J Radiat Oncol Biol Phys, 2015 Jul 15

Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer.

Pract Radiat Oncol, 2015 Sep-Oct

Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.

Int J Radiat Oncol Biol Phys, 2013 Oct 1

Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.

Lancet Oncol., 2015 Dec 16

Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.

Lancet,

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

Int. J. Radiat. Oncol. Biol. Phys., 2014 Feb 01

Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.

Cancer, 1999-10-15

Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae.

Int. J. Radiat. Oncol. Biol. Phys., 2002-05-01

Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.

Ann. Thorac. Surg., 2001-05-01

Evolving management and outcome of esophageal cancer with airway involvement.

J Clin Oncol, 2011 Nov 1

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

J Can Assoc Radiol, 1981-09-01

Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.

J. Clin. Oncol., 1985-03-01

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.

J. Natl. Cancer Inst., 1988-07-20

Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.

Ann. Oncol., 2008-09-01

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Gastrointest Cancer Res, 2007 Mar

Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.

Int J Radiat Oncol Biol Phys, 2010 May 1

Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.

Med Dosim, 2016-01-01

Urethral dose sparing in squamous cell carcinoma of anal canal using proton therapy matching electrons with prior brachytherapy for prostate cancer: A case study.

Int J Radiat Oncol Biol Phys, 2008 Nov 1

Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.

Int J Radiat Oncol Biol Phys, 2013 Jul 1

Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Br. J. Cancer, 2005-04-11

Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.

Cancer,

External radiation therapy without chemotherapy in the management of anal cancer.

Dis. Colon Rectum,

A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients.

Int J Radiat Oncol Biol Phys, 2015 Feb 3

Predictors of Toxicity Associated With Stereotactic Body Radiation Therapy to the Central Hepatobiliary Tract.

Pract Radiat Oncol, 2016 Jan-Feb

Practical implementation of quality improvement for high-dose-rate brachytherapy.

J Clin Oncol, 2016 Feb 10

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Semin. Oncol., 2001-06-01

Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.

J. Clin. Oncol., 2018 Nov 07

Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

JAMA, 1999-05-05

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Cancer, 2000-01-15

Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review.

Ann. Oncol., 2008-03-01

Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience.

Radiother Oncol, 2014 Oct

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Med Phys, 2003-03-01

How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: equivalent uniform dose or tumor control probability?

Cancer, 2009-12-01

Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience.

Ann. Surg., 2016-07-01

A Propensity-matched Analysis Comparing Survival After Esophagectomy Followed by Adjuvant Chemoradiation to Surgery Alone for Esophageal Squamous Cell Carcinoma.

J Clin Oncol, 2012 Jan 20

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Lancet Oncol., 2018 Apr 09

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Dis. Colon Rectum, 2014-04-01

Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.

Clin Oncol (R Coll Radiol), 2017-04-01

Are there HIV-specific Differences for Anal Cancer Patients Treated with Standard Chemoradiotherapy in the Era of Combined Antiretroviral Therapy?

Can Fam Physician,

Managing hiccups.

J Natl Compr Canc Netw, 2014 Apr 1

Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

Br J Surg, 2002-11-01

Salvage abdominoperineal resection in anal epidermoid cancer.

Cochrane Database Syst Rev, 2015-05-22

Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances.

Ann. Thorac. Surg., 2003-11-01

Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer.

Eur J Surg, 2001-11-01

Percutaneous endoscopic gastrostomy for nutrition in patients with oesophageal cancer.

Am. J. Surg., 2014-03-01

Esophagectomy in patients with prior percutaneous endoscopic gastrostomy tube placement.

J. Am. Coll. Surg., 2015-03-01

Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes.

Gynecol. Oncol., 1991-07-01

Changing concepts in the management of vulvar cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2017-02-01

Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.

Cancer, 2010 Sep 1

Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.

J. Clin. Oncol., 2004-04-15

Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer.

Int J Radiat Oncol Biol Phys, 2016 Mar 15

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.

Int J Radiat Oncol Biol Phys, 2005 Dec 1

Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.

N. Engl. J. Med., 2004-10-21

Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Lancet Oncol., 2015-08-01

High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.

J. Natl. Cancer Inst., 2016-12-01

Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.

Lancet, 2017-07-29

Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.

Pract Radiat Oncol, 2012 Oct-Dec

Palliative radiotherapy in patients with esophageal carcinoma: A retrospective review.

Curr Oncol, 2012-04-01

What is the optimal management of dysphagia in metastatic esophageal cancer?

Int. J. Radiat. Oncol. Biol. Phys., 2013-03-15

Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.

Pract Radiat Oncol, 2017 Sep - Oct

Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?

J Clin Oncol, 2005 Dec 1

Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.

Liver Transpl, 2014 Jan

Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.

Adv Radiat Oncol, 2016 Oct-Dec

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.

J. Hepatol., 2017-07-01

Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.

Liver Transpl., 2012-08-01

Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.

Adv Radiat Oncol, 2016 Jan-Mar

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.

Liver Transpl., 2013-10-01

Down-staging of hepatocellular carcinoma via external-beam radiotherapy with subsequent liver transplantation: a case report.

Future Oncol, 2016-07-01

Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe?

Cancer Med, 2016-12-01

Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma.

Am J Clin Oncol, 2016 Oct 17

Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.

Radiother Oncol, 2017 Jan 2

Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.

J. Clin. Oncol., 2016-08-10

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Lancet Oncol., 2014-07-01

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Ann. Oncol., 2014-07-01

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.

J. Clin. Oncol., 2015-10-01

Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.

J Clin Oncol, 2012 Dec 10

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin.

Lancet Oncol., 2013-05-01

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Radiat Oncol, 2014 May 29

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.

Br. J. Cancer, 2014 Aug 28

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.

J Gastrointest Cancer,

Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.

J Clin Oncol, 2009 Apr 1

Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.

Acta Oncol, 2006-01-01

Phase II study on stereotactic body radiotherapy of colorectal metastases.

J. Cancer Res. Clin. Oncol., 2015-07-01

The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).

Semin Radiat Oncol, 2017-07-01

Stereotactic Body Radiotherapy for Liver Metastases.

Int. J. Radiat. Oncol. Biol. Phys., 1988-05-01

Reflections in rectosigmoid: retro-peritoneal vs. intra-peritoneal.

Int J Radiat Oncol Biol Phys, 2016 Jul 15

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study.

J Geriatr Oncol, 2017-09-20

Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy.

Int. J. Radiat. Oncol. Biol. Phys., 2001-01-01

Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.

Lancet Gastroenterol Hepatol, 2017-07-01

A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.

Dis. Colon Rectum, 2017-10-01

Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection - A Matched-Controlled Study.

Ann. Oncol., 2016-05-01

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.

Int. J. Radiat. Oncol. Biol. Phys., 2017-10-01

Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.

Ann. Surg., 2015-09-01

Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.

J Vasc Interv Radiol, 2017-03-01

Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma.

N. Engl. J. Med., 2001-08-30

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

J. Clin. Oncol., 2005-09-01

Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.

Lancet Oncol., 2017-03-01

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

Int J Radiat Oncol Biol Phys, 2003 Mar 1

Chemoradiation for adenocarcinoma of the anus.

Int. J. Radiat. Oncol. Biol. Phys., 2012 Aug 14

Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.

Pract Radiat Oncol, 2016 Sep 07

Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy.

Radiother Oncol, 2012 Feb 22

Systematic review of the role of a belly board device in radiotherapy delivery in patients with pelvic malignancies.

Radiother Oncol, 2011 Jun 30

Bowel exposure in rectal cancer IMRT using prone, supine, or a belly board.

Br J Surg,

Epidermoid cancer of the anus.

Proc. R. Soc. Med.,

Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark's Hospital 1928-66.

Lancet Oncol., 2011 May 17

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

J Clin Oncol, 2008 Mar 20

Effects of chemoradiation on tumor-host interactions: the immunologic side.

J. Clin. Oncol.,

Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?

Pract Radiat Oncol, 2014 Nov 6

Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system.

Radiother Oncol, 2014 Jun

Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma.

J Clin Oncol, 2013 May 1

Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.

J Clin Oncol, 2016 Feb 10

Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

J. Natl. Cancer Inst.,

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Int J Radiat Oncol Biol Phys, 2005 Dec 1

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

N Engl J Med, 2007 Aug 16

Prophylactic cranial irradiation in extensive small-cell lung cancer.

N. Engl. J. Med., 1999-08-12

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Radiother Oncol, 2011 Oct 10

Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?

Int. J. Radiat. Oncol. Biol. Phys.,

Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal.

Ann. Oncol.,

Incidence of second tumors after treatment with or without radiation for rectal cancer.

Br J Surg, 2016 Nov 01

Risk of second primary cancer in patients treated with radiotherapy for rectal cancer.

Int. J. Radiat. Oncol. Biol. Phys.,

Role of positron emission tomography-computed tomography in the management of anal cancer.

Int J Radiat Oncol Biol Phys, 2014 Nov 1

Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.

Radiother Oncol, 2016 Aug

Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer.

J. Thorac. Cardiovasc. Surg., 2014 Feb 10

Supraclavicular node metastasis from thoracic esophageal carcinoma: A surgical series from a Japanese multi-institutional nationwide registry of esophageal cancer.

Int J Radiat Oncol Biol Phys, 2008 Jul 15

Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.

Clin Transl Radiat Oncol, 2017 Jun

Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus.

Radiat Oncol,

Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients.

Gastroenterology,

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Int. J. Radiat. Oncol. Biol. Phys.,

Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases.

Lancet,

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.

Cancer,

A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group.

J. Clin. Oncol.,

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

Radiother Oncol, 2012 Aug

Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.

J. Clin. Oncol., 2009 May 18

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Radiother Oncol, 2019 Apr

Adjuvant radiation therapy for T4 non-rectal colon adenocarcinoma provides a cause-specific survival advantage: A SEER database analysis.

Int. J. Radiat. Oncol. Biol. Phys.,

Reirradiation for rectal cancer and surgical resection after ultra high doses.

Int J Radiat Oncol Biol Phys, 2016 Dec 1

Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.

Int. J. Radiat. Oncol. Biol. Phys.,

Radiation myelitis and survival in the radiotherapy of lung cancer.

Brachytherapy, 2018 Feb 26

Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer.

J Clin Oncol, 2014 Feb 20

Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Br J Radiol, 2017 Aug

Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

J. Clin. Oncol., 2013 Nov 25

Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.

Adv Radiat Oncol, 2018 Jul 17

Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation.

BMJ, 2006 Sep 19

Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.

BMC Palliat Care, 2015 Aug 04

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study.

Radiother Oncol, 2014 Aug

Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.

Int J Radiat Oncol Biol Phys, 2015 Sep 1

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Int. J. Radiat. Oncol. Biol. Phys., 2018 Mar 02

Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?

Int. J. Radiat. Oncol. Biol. Phys., 2017 Jun 26

Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.

Int J Radiat Oncol Biol Phys, 2009 Nov 1

Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.

Int. J. Radiat. Oncol. Biol. Phys., 2008 Jan 30

Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.

Thorac Surg Clin,

Management of Malignant Tracheoesophageal Fistula.

Int J Radiat Oncol Biol Phys, 2017 Feb 1

Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

Cancer, 2012 Dec 1

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.

Int J Radiat Oncol Biol Phys, 2016 May 1

Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis.

JAMA Oncol,

Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.

Gastroenterology, 2012 Apr 12

Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.

HPB (Oxford), 2015 Feb

Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ? 3 cm.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Sep 14

Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.

Lancet, 2019 Apr 11

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Ann. Surg. Oncol., 2017 Mar 23

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.

J Clin Oncol, 2018 Jul 1

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

Lancet Oncol., 2017 Oct 26

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Lancet Oncol., 2017 Aug 03

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

JAMA Oncol,

Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.

Radiation Oncology

Gastrointestinal Cancers

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology